Pacer Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.9M | Sell |
192,847
-81,982
| -30% | -$18.2M | 0.12% | 201 |
|
|
2025
Q4 | $62.8M | Sell |
274,829
-190,155
| -41% | -$43.3M | 0.16% | 142 |
|
|
2025
Q3 | $108M | Sell |
464,984
-32,717
| -7% | -$6.66M | 0.27% | 78 |
|
|
2025
Q2 | $92.4M | Buy |
497,701
+127,289
| +34% | +$23.7M | 0.23% | 96 |
|
|
2025
Q1 | $77.6M | Sell |
370,412
-17,590
| -5% | -$3.42M | 0.18% | 110 |
|
|
2024
Q4 | $68.9M | Sell |
388,002
-3,913
| -1% | -$719K | 0.15% | 159 |
|
|
2024
Q3 | $77.4M | Buy |
391,915
+19,025
| +5% | +$3.55M | 0.16% | 154 |
|
|
2024
Q2 | $64M | Sell |
372,890
-23,492
| -6% | -$3.89M | 0.14% | 171 |
|
|
2024
Q1 | $72.2M | Sell |
396,382
-2,456,367
| -86% | -$423M | 0.17% | 157 |
|
|
2023
Q4 | $442M | Buy |
2,852,749
+382,406
| +15% | +$55.8M | 1.25% | 2 |
|
|
2023
Q3 | $368M | Buy |
2,470,343
+256,318
| +12% | +$37.6M | 1.41% | 3 |
|
|
2023
Q2 | $298M | Buy |
2,214,025
+363,583
| +20% | +$53.3M | 1.2% | 4 |
|
|
2023
Q1 | $295M | Buy |
1,850,442
+1,758,035
| +1,902% | +$269M | 1.26% | 3 |
|
|
2022
Q4 | $14.9M | Sell |
92,407
-1,118,399
| -92% | -$171M | 0.08% | 208 |
|
|
2022
Q3 | $163M | Buy |
1,210,806
+1,069,033
| +754% | +$153M | 1.13% | 6 |
|
|
2022
Q2 | $21.7M | Buy |
141,773
+10,316
| +8% | +$1.58M | 0.16% | 112 |
|
|
2022
Q1 | $21.3M | Sell |
131,457
-217,311
| -62% | -$31.6M | 0.17% | 109 |
|
|
2021
Q4 | $47.2M | Buy |
348,768
+61,151
| +21% | +$7.22M | 0.48% | 24 |
|
|
2021
Q3 | $31M | Buy |
287,617
+156,466
| +119% | +$17.9M | 0.39% | 28 |
|
|
2021
Q2 | $14.8M | Buy |
131,151
+11,097
| +9% | +$1.25M | 0.21% | 72 |
|
|
2021
Q1 | $13M | Sell |
120,054
-8,213
| -6% | -$878K | 0.23% | 59 |
|
|
2020
Q4 | $13.7M | Sell |
128,267
-32,213
| -20% | -$3.1M | 0.26% | 57 |
|
|
2020
Q3 | $14.1M | Sell |
160,480
-69,135
| -30% | -$6.51M | 0.3% | 58 |
|
|
2020
Q2 | $22.5M | Buy |
229,615
+144,244
| +169% | +$12.7M | 0.46% | 42 |
|
|
2020
Q1 | $7.12M | Buy |
85,371
+39,288
| +85% | +$3.35M | 0.14% | 59 |
|
|
2019
Q4 | $4.08M | Sell |
46,083
-239,765
| -84% | -$19.9M | 0.18% | 94 |
|
|
2019
Q3 | $21.6M | Buy |
285,848
+25,514
| +10% | +$1.75M | 0.49% | 38 |
|
|
2019
Q2 | $18.9M | Buy |
260,334
+22,778
| +10% | +$1.79M | 0.46% | 38 |
|
|
2019
Q1 | $19.1M | Buy |
237,556
+155,097
| +188% | +$12.7M | 0.53% | 31 |
|
|
2018
Q4 | $7.6M | Sell |
82,459
-72,445
| -47% | -$6.37M | 0.27% | 5 |
|
|
2018
Q3 | $14.7M | Buy |
154,904
+48,712
| +46% | +$4.62M | 0.55% | 26 |
|
|
2018
Q2 | $9.84M | Buy |
106,192
+45,016
| +74% | +$4.4M | 0.45% | 29 |
|
|
2018
Q1 | $5.79M | Buy |
61,176
+5,525
| +10% | +$607K | 0.32% | 47 |
|
|
2017
Q4 | $5.38M | Sell |
55,651
-9,306
| -14% | -$877K | 0.38% | 36 |
|
|
2017
Q3 | $5.77M | Buy |
64,957
+5,399
| +9% | +$411K | 0.51% | 21 |
|
|
2017
Q2 | $4.32M | Buy |
59,558
+11,704
| +24% | +$787K | 0.43% | 29 |
|
|
2017
Q1 | $3.12M | Buy |
47,854
+5,881
| +14% | +$370K | 0.38% | 36 |
|
|
2016
Q4 | $2.63M | Buy |
41,973
+3,151
| +8% | +$192K | 0.37% | 38 |
|
|
2016
Q3 | $2.45M | Buy |
38,822
+825
| +2% | +$53.4K | 0.37% | 39 |
|
|
2016
Q2 | $2.35M | Buy |
37,997
+8,527
| +29% | +$520K | 0.37% | 46 |
|
|
2016
Q1 | $1.68M | Buy |
29,470
+3,966
| +16% | +$221K | 0.38% | 53 |
|
|
2015
Q4 | $1.51M | Buy |
+25,504
| New | +$1.47M | 0.36% | 54 |
|
|
2013
Q4 | $437K | Buy |
+6,671
| New | +$328K | 0.11% | 246 |
|
Other funds holding ABBV
VCM
VPM
Pacer Advisors's ABBV Position: Q1 2026 in Review
Pacer Advisors reduced its AbbVie (ABBV) stake by 30% in Q1 2026, selling an estimated $18.2M and leaving 192,847 shares worth $41.9M. The position accounts for 0.12% of the portfolio, ranked #201.
Pacer Advisors first reported a position in ABBV in Q4 2013 and has held it in 43 quarters since. The position peaked at $442M in Q4 2023. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Pacer Advisors held 192,847 shares of AbbVie worth $41.9M as of Q1 2026.
- Pacer Advisors sold 81,982 AbbVie shares in Q1 2026, an estimated $18.2M.
- AbbVie made up 0.12% of Pacer Advisors's portfolio in Q1 2026, its #201 holding.
- Pacer Advisors first reported a position in AbbVie in Q4 2013 and has held it in 43 quarters since.
- Pacer Advisors's AbbVie position peaked at $442M in Q4 2023.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.